Investor profile
Jim Sullivan
Family Office, Private equity, Venture capital, Venture debt & Venture Partner at OrbiMed, Adjunct Professor, Department of Pharmacology at Northwestern University Medill School
Jim Sullivan is a Venture Partner at OrbiMed, whose known portfolio counts 12 companies.
Is Jim Sullivan a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
- Focus
- BiotechDiagnosticsDigital HealthDrug DiscoveryGeneticsLife ScienceMedical DevicesPrecision MedicineTherapeuticsUniversity Venture Fund
Contacts
Affiliated funds' portfolios
Venture Partner at OrbiMed, whose known portfolio counts 12 companies
- ADCendo
- Congruence Therapeutics
- Pulnovo Medical
- Terremoto Biosciences
- Nucleus RadioPharma
- Pinnacle Medicines
- Sidewinder Therapeutics
- ImageneBio
- Microtide Biotechnology
- Proviva Therapeutics
- Innovative Spinal Technologies
- SpectronRx
Adjunct Professor, Department of Pharmacology at Northwestern University Medill School, whose known portfolio counts 9 companies
- Ocient
- Aptinyx
- Gearflow
- Asensei
- Solovis
- Stemloop
- Lakeside Discovery
- Tanvas
- Trim
Investor Profile
Jim Sullivan is listed against sectors AI, Education, Hardware and Healthcare, and focus areas Biotech, Diagnostics, Digital Health and Drug Discovery in the database.
OrbiMed appears in Growth, Late-Stage and Pre-Seed rounds across its known deals.
The firm portfolio and the focus above give founders context on whether Jim Sullivan matches their raise.
Colleagues
Showing 20 of 41
Dave Donnan
Adjunct Professor
Canmore, Canada
Marty Ringlein
Adjunct Professor
Brooklyn, United States
Craig Wortmann
Investor
Evanston, United States
Kristin McDonnell
President, Northwestern Alumni Association
Menlo Park, United States
David Scalzo
Chair
Winter Park, United States
Tom Biegala
Adjunct Professor
San Francisco, United States
Dimitri Krainc
Venture Partner
Chicago, United States
Jonathan Silverstein
Investor
New York, United States
Jeremy Barnis
Venture Capitalist
Germany
Peter Thompson
General Partner
Bellevue, United States
Evan Caplan
Partner
San Francisco, United States
Jonathan Mandelbaum
Principal
New York, United States
Carl Gordon
Managing Partner
New York City, United States
Kipyegon Kitur
Principal
New York, United States
Carter Neild
Managing Partner
New York, United States
Geoffrey Hsu
General Partner
New York, United States
Topher Orr
Partner
New York, United States
Vivek Sivathanu
Principal
San Francisco, United States
Scotland Stevens
General Partner
New York, United States
Brendan Weber
Principal
New York City, United States
Frequently asked questions
Who is Jim Sullivan?
Jim Sullivan is a family office investor and private equity investor based in Chicago, Illinois, United States, listed as Venture Partner at OrbiMed. The known portfolio of that firm counts 12 companies. That portfolio belongs to the firm, not to Jim Sullivan personally.
What does Jim Sullivan invest in?
Listed sectors include AI, Education, Hardware and Healthcare; listed focus areas include Biotech, Diagnostics, Digital Health and Drug Discovery. Those tags come from the portfolios of the firms this profile is attached to, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Jim Sullivan invest at?
OrbiMed appears in Growth, Late-Stage and Pre-Seed rounds across its known deals, and Jim Sullivan is listed there as Venture Partner. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Jim Sullivan listed at?
Jim Sullivan is listed as Venture Partner at OrbiMed. 41 other people in the database share a firm with Jim Sullivan.
How do I contact Jim Sullivan?
An email address, a phone number and a LinkedIn page are on file for Jim Sullivan. The address stays masked on this page and is readable inside RaiseHunt after you create an account.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal